Sanofi’s BTK inhibitor meets primary endpoint in Phase 2b to treat MS
Category: #health  By Saipriya Iyer  Date: 2020-02-08
  • share
  • Twitter
  • Facebook
  • LinkedIn

Sanofi’s BTK inhibitor meets primary endpoint in Phase 2b to treat MS

MS (multiple sclerosis) is a serious disease that affects about 1.2 million people across the U.S. and Europe. The ailment is a chronic disease that attacks the CNS (central nervous system). Today, despite present therapies, several MS patients continue to face disability, with one in four of the MS patients suffering from a progressive forms of this disease with no treatments or very limited treatments available. Global pharmaceutical companies are working diligently to find a cure.

A recent effort in this regard came to light when Sanofi, a renowned French pharmaceutical company, reportedly announced that its investigational BTK inhibitor achieved its primary endpoint in the Phase 2b trial. The company’s Bruton's tyrosine kinase (BTK) inhibitor (SAR442168) is a brain-penetrant, oral, and selective small-molecule developed to address multiple sclerosis.

In the Phase 2b study, the BTK inhibitor significantly decreased the disease activity associated with MS, as per measurements done using MRI (magnetic resonance imaging). SAR442168 inhibitor was well tolerated along with no novel safety findings.

The SAR442168 is considered to modulate both innate (CNS microglial cells) and adaptive (B-cell activation) immune cells associated with neuroinflammation in the spinal cord and brain. 

Sanofi’s Global Head of Research and Development, John Reed, M.D., Ph.D. stated that majority of people suffering from MS still endure disability in the course of this disease. The company believes that its BTK inhibitor has the ability to change how multiple sclerosis is treated. This inhibitor might be the first B-cell-targeted MS treatment that hinders the peripheral immune system and crosses the blood-brain barrier to block immune cells that have moved to the brain, while modulating the brain-resident microglia cells which are being implicated in micro sclerosis progression as well.  

Reed further added that building on the company’s heritage in MS, the company is thrilled by these clinical outcomes and looks forward to advance its brain penetrant SAR442168 inhibitor into pivotal clinical studies.

Four Phase 3 studies would further investigate the SAR442168 inhibitor’s effect on multiple sclerosis relapse rates, underlying CNS (central nervous system) damage, and disability progression. Phase 3 studies in progressive and relapsing forms of the MS are scheduled to start during the mid-2020.

Source credit: https://www.sanofi.com/en/media-room/press-releases/2020/2020-02-06-07-00-00



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

PharmaCyte to submit IND application to FDA for clinical trial in LAPC
PharmaCyte to submit IND application to FDA for clinical trial in LAPC
By Saipriya Iyer

PharmaCyte Biotech, a clinical-stage biotechnology company, is reportedly set to submit an IND (Investigational New Drug) application to the U.S. FDA. The IND application is related to the Phase 2b clinical trial among...

Immunic announces topline data from Phase 2 EMPhASIS, IMU-838 trial
Immunic announces topline data from Phase 2 EMPhASIS, IMU-838 trial
By Saipriya Iyer

Immunic, Inc. has recently announced positive topline results from the Phase 2 EMPhASIS trial of IMU-838, in patients with RRMS (relapsing-remitting multiple sclerosis). IMU-838 is a next-generation, orally available s...

Ciox announces acquisition of biomed-NLP technology company, Medal
Ciox announces acquisition of biomed-NLP technology company, Medal
By Saipriya Iyer

Ciox Health has recently announced the acquisition of Medal, Inc., a biomed-NLP (biomedical Natural Language Processing) technology company based in San Francisco. Medal is also a leader in integrating AI techniques fo...